Last Updated: November 16, 2026

Investigational Drug Information for LNP023

« Back to Dashboard


What is the drug development status for LNP023?

LNP023 is an investigational drug.

There have been 23 clinical trials for LNP023. The most recent clinical trial was a Phase 2 trial, which was initiated on July 28th 2025.

The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Kidney Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for LNP023
TitleSponsorPhase
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsNovartis PharmaceuticalsPHASE3
Iptacopan in Patients With ANCA Associated VasculitisNovartis PharmaceuticalsPHASE2
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Novartis PharmaceuticalsPhase 3

See all LNP023 clinical trials

Clinical Trial Summary for LNP023

Top disease conditions for LNP023
Top clinical trial sponsors for LNP023

See all LNP023 clinical trials

US Patents for LNP023

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LNP023 ⤷  Start Trial Polycyclic compounds as lysophosphatidic acid receptor antagonists Amira Pharmaceuticals Inc ⤷  Start Trial
LNP023 ⤷  Start Trial Therapeutic/ preventive agent containing coumarin derivative as active ingredient Nippon Zoki Pharmaceutical Co Ltd ⤷  Start Trial
LNP023 ⤷  Start Trial Ketene imine compound, polyester film, back sheet for solar cell module, and solar cell module Fujifilm Corp ⤷  Start Trial
LNP023 ⤷  Start Trial Quinazolinone and isoquinolinone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (Tokyo, JP) ⤷  Start Trial
LNP023 ⤷  Start Trial Carboxamide derivatives and use thereof Purdue Pharma LP ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LNP023

Drugname Country Document Number Estimated Expiration Related US Patent
LNP023 Argentina AR078495 2029-10-01 ⤷  Start Trial
LNP023 Australia AU2010300594 2029-10-01 ⤷  Start Trial
LNP023 Brazil BR112012007102 2029-10-01 ⤷  Start Trial
LNP023 Canada CA2776779 2029-10-01 ⤷  Start Trial
LNP023 Chile CL2012000812 2029-10-01 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent
Last updated: October 11, 2026

LNP023, now marketed as iptacopan under the brand Fabhalta, is a first-in-class oral factor B inhibitor developed by Novartis. As of June 2024, its commercial foundation is FDA approval for adults with paroxysmal nocturnal hemoglobinuria (PNH), while phase 3 programs target C3 glomerulopathy (C3G) and immunoglobulin A nephropathy (IgAN). Novartis has identified Fabhalta as a potential multibillion-dollar product, with peak annual sales potential above $3 billion, but that outcome depends on successful renal-indication approvals and durable reimbursement.

LNP023 Iptacopan Development Update and Market Projection

What is LNP023 and how does iptacopan work?

LNP023 is the development code for iptacopan, an oral, selective inhibitor of complement factor B. Factor B is part of the alternative complement pathway. Blocking factor B reduces formation and amplification of the alternative-pathway C3 convertase, limiting downstream complement activation.

Attribute LNP023 / iptacopan
Generic name Iptacopan
Brand Fabhalta
Developer Novartis
Mechanism Oral selective factor B inhibition
Modality Small molecule
Initial indication Paroxysmal nocturnal hemoglobinuria
Key development indications C3G, IgAN
Administration Oral, twice daily
Regulatory class New molecular entity
Primary commercial advantage Oral pathway inhibition without infusion administration

Iptacopan differs from terminal complement inhibitors such as eculizumab and ravulizumab because it acts upstream at factor B. It also differs from C3 inhibitors such as pegcetacoplan, which directly inhibit C3 but require parenteral administration.

What is the FDA status of Fabhalta for PNH?

The FDA approved Fabhalta on December 15, 2023, for adults with PNH to reduce hemolysis. The approval was based principally on the APPLY-PNH and APPOINT-PNH programs. APPLY-PNH evaluated patients with residual anemia despite treatment with C5 inhibitors. APPOINT-PNH evaluated patients who had not previously received complement inhibitors.

The FDA label established Fabhalta as an oral treatment option for both complement-inhibitor-experienced and complement-inhibitor-naive PNH patients. The clinical value proposition is strongest in patients with extravascular hemolysis and anemia that remain inadequately controlled on C5 inhibition.

Key safety and administration requirements include:

  • Increased risk of serious infections caused by encapsulated bacteria.
  • Vaccination requirements before treatment when feasible.
  • Antibiotic management when vaccination cannot be completed before therapy.
  • Twice-daily oral dosing.
  • Monitoring for breakthrough hemolysis and thrombotic complications.

The European Commission authorized Fabhalta for PNH in 2024. The U.S. and European approvals give Novartis a regulatory base for expansion into other complement-mediated diseases. (U.S. Food and Drug Administration, 2023; European Commission, 2024)

What are the main clinical development programs for LNP023?

C3 glomerulopathy

The APPEAR-C3G phase 3 trial evaluates iptacopan in patients with C3G, a rare kidney disease driven by dysregulated alternative-pathway complement activity. The study is designed around proteinuria and renal-function outcomes, including changes in the urine protein-to-creatinine ratio and estimated glomerular filtration rate.

C3G is commercially important because it has no broadly established disease-modifying standard of care. Existing management often includes supportive kidney care, immunosuppression in selected patients and, in severe cases, kidney transplantation. Recurrence after transplantation creates a continuing treatment need.

A positive C3G result would support a high-value orphan-drug positioning. The addressable population is small, but chronic treatment, severe disease burden and limited alternatives could support premium pricing.

Immunoglobulin A nephropathy

The APPLAUSE-IgAN phase 3 trial evaluates iptacopan in adults with IgAN at risk of progressive kidney disease. The disease population is substantially larger than C3G, but competition is more developed.

Relevant competitors include:

  • Targeted-release budesonide, marketed as Tarpeyo in the United States.
  • Sparsentan, marketed as Filspari.
  • Broad renin-angiotensin system blockade.
  • SGLT2 inhibitors used in patients with appropriate renal and metabolic profiles.
  • Emerging complement-directed therapies.

The IgAN opportunity could be materially larger than the C3G opportunity, but pricing and formulary access will face greater scrutiny. Payers are likely to require evidence of durable renal-function preservation rather than proteinuria reduction alone.

Additional complement-mediated diseases

Novartis has investigated iptacopan in other complement-mediated conditions, including immune-complex and hematologic diseases. The commercial strategy has centered on indications in which alternative-pathway activity is sufficiently important to produce a measurable treatment response.

Not every earlier program has the same probability of success. The highest-value development path remains PNH, C3G and IgAN because these indications have defined biology, clinical endpoints and identifiable specialist prescribers.

When did LNP023 lose exclusivity, and when could generic entry occur?

The principal U.S. regulatory exclusivity period for Fabhalta began with FDA approval in December 2023. As an orphan drug, Fabhalta received seven years of U.S. orphan exclusivity for PNH, subject to the scope of the approved indication and statutory exceptions. That period would ordinarily run into December 2030.

FDA new-chemical-entity exclusivity is generally five years. For an NCE approved in December 2023, the practical NCE exclusivity period would generally extend into December 2028, although the precise date depends on FDA regulatory calculations.

Patent protection could extend beyond regulatory exclusivity. Novartis’ protection is expected to include composition-of-matter, pharmaceutical-composition, therapeutic-use and manufacturing claims. The effective generic-entry date will depend on:

  1. The expiration dates of issued U.S. patents.
  2. Any patent-term adjustment or extension.
  3. Orange Book listing decisions.
  4. Paragraph IV litigation.
  5. Settlement terms with generic applicants.
  6. Pediatric exclusivity or other statutory extensions.

A reliable patent-expiration date cannot be inferred from the approval date alone. The relevant patents must be confirmed in the current FDA Orange Book and USPTO records.

What patents protect iptacopan and what is the Orange Book status?

Iptacopan’s patent estate is expected to include several claim categories:

Patent category Commercial purpose
Compound patents Protect the active iptacopan molecule and related chemical scope
Salt and polymorph patents Protect solid-state forms used in commercial manufacture
Formulation patents Protect oral dosage forms, excipients and stability profiles
Method-of-use patents Protect treatment of PNH, C3G, IgAN and other complement diseases
Manufacturing patents Protect synthesis, intermediates and process controls
Combination patents Protect use with other complement or kidney-disease therapies

For a small molecule, composition-of-matter protection is normally the most valuable layer. Method-of-use patents can delay competitive substitution but are more vulnerable to carve-outs and skinny-label strategies.

Fabhalta is expected to have Orange Book-listed patents associated with its approved PNH product. The scope and expiration dates of those listings should be evaluated against the current Orange Book rather than relying on secondary patent databases. As of June 2024, no publicly established U.S. Paragraph IV challenge had materially altered the commercial outlook for Fabhalta.

Which companies are challenging LNP023?

As of June 2024, no major publicly reported Paragraph IV litigation against Fabhalta had established a near-term generic launch risk. The likely challengers would be large generic manufacturers with experience in complex small molecules and specialty products.

The more immediate competitive risks are branded therapies rather than generics:

  • AstraZeneca, through ravulizumab and eculizumab, remains a major PNH competitor.
  • Apellis competes with pegcetacoplan in PNH.
  • Danicopan, developed by AstraZeneca, competes through oral factor D inhibition in selected PNH settings.
  • Travere Therapeutics and other kidney-focused companies compete in IgAN.
  • Additional complement inhibitors may enter C3G and IgAN.

How does Fabhalta compare with competing PNH drugs?

Product Target Route Main commercial strength Main limitation
Fabhalta Factor B Oral Oral dosing and control of intravascular and extravascular hemolysis Twice-daily dosing; infection precautions
Soliris C5 Intravenous Established efficacy and long clinical history Infusion burden and residual extravascular hemolysis
Ultomiris C5 Intravenous Less frequent dosing than Soliris Infusion administration and residual disease
Empaveli C3 Subcutaneous Broad complement blockade Injection burden and tolerability
Voydeya Factor D Oral add-on Addresses residual hemolysis in selected C5-treated patients Initially positioned as add-on therapy rather than broad replacement

Fabhalta’s strongest differentiation is the combination of oral administration and upstream alternative-pathway inhibition. The product may convert some patients from infused C5 therapy, but switching will depend on physician confidence, vaccination compliance, safety monitoring and payer policy.

What is the market projection for iptacopan?

Novartis has publicly indicated peak sales potential above $3 billion for Fabhalta. That figure assumes expansion beyond PNH, particularly into C3G and IgAN. A reasonable commercial framework is:

Scenario Core assumptions Peak annual sales range
Downside PNH uptake is gradual; renal indications are delayed or restricted $0.8 billion-$1.5 billion
Base case Strong PNH adoption, C3G approval and moderate IgAN penetration $2.0 billion-$3.5 billion
Upside Broad renal approvals, durable efficacy and strong conversion from infused therapies $4.0 billion-$6.0 billion

These are scenario estimates, not company guidance. The largest variables are renal-indication approval, duration of treatment, net price, payer restrictions and the number of patients treated chronically.

PNH revenue potential

PNH is a rare disease with a limited patient pool, so PNH alone is unlikely to support the upper end of the company’s sales ambition. Fabhalta can generate substantial revenue in PNH because treatment is chronic and specialty-drug pricing is high.

Commercial adoption should come from three groups:

  1. Patients inadequately controlled on C5 inhibitors.
  2. Newly diagnosed patients eligible for complement inhibition.
  3. Patients seeking an oral alternative to infusion therapy.

The second group may be slower to convert because physicians have extensive experience with C5 inhibitors and may prefer established long-term safety data.

C3G revenue potential

C3G could produce high revenue per patient because of disease severity and limited alternatives. The population is small, but diagnosis is concentrated in specialist nephrology centers. Reimbursement may depend heavily on evidence of preserved kidney function and reduced progression to end-stage kidney disease.

IgAN revenue potential

IgAN is the largest potential population among iptacopan’s lead indications. It also carries the greatest competitive and pricing risk. Payers may use step therapy, require high-risk disease criteria and favor products with demonstrated long-term renal outcomes.

If approved, IgAN could contribute more absolute revenue than PNH or C3G, but it is unlikely to reach broad primary-care utilization. Prescribing will remain concentrated among nephrologists.

What licensing deals affect LNP023?

Iptacopan originated from Novartis’ internal complement research and is not principally dependent on a major external licensing transaction. The commercial rights are controlled by Novartis, which has funded development, regulatory filings and commercialization.

The absence of a major co-commercialization partner gives Novartis control over pricing, sequencing and indication expansion. It also leaves Novartis responsible for the full cost of global launch and post-approval studies.

What manufacturing and intellectual-property barriers protect iptacopan?

Generic competition will face more than the challenge of reproducing the active ingredient. Relevant barriers may include:

  • Control of the commercial solid form.
  • Reproducible synthesis of complex intermediates.
  • Impurity specifications.
  • Stability and dissolution performance.
  • Bioequivalence for a twice-daily oral product.
  • Patent claims covering salts, polymorphs or formulations.
  • Regulatory requirements for specialized labeling and risk management.

These barriers are meaningful but not equivalent to biologic manufacturing barriers. Iptacopan is a small molecule, so eventual generic competition is structurally more feasible than biosimilar competition against a monoclonal antibody.

Is there biosimilar risk for Fabhalta?

Fabhalta has no biosimilar risk because iptacopan is a chemically synthesized small molecule. The relevant long-term threat is conventional generic entry through an abbreviated new drug application.

Biosimilar competition remains relevant to the broader complement market. Ravulizumab and eculizumab face eventual biosimilar pressure, which could lower the cost of infused C5 inhibition and reduce Fabhalta’s switching advantage. Conversely, lower C5 prices could expand overall complement treatment and create more patients eligible for alternative-pathway therapies.

How strong is the iptacopan patent estate?

The estate appears commercially strong through the early post-launch period because Fabhalta combines regulatory exclusivity with multiple likely patent layers and an orphan-disease positioning. Its principal vulnerability is timing. If composition-of-matter protection expires materially before 2035, method-of-use and formulation patents would carry greater importance.

Patent strength should be assessed on four dimensions:

Dimension Assessment
Regulatory exclusivity Strong through the late 2020s and PNH orphan exclusivity into approximately 2030
Composition protection Likely the critical barrier, subject to issued claims and expiration data
Formulation protection Potentially useful but generally narrower than compound claims
Method-of-use protection Important for renal indications but exposed to label carve-outs

Key Takeaways

  • LNP023 is iptacopan, marketed by Novartis as Fabhalta.
  • FDA approval was granted in December 2023 for adults with PNH.
  • The principal expansion opportunities are C3G and IgAN.
  • PNH provides the initial revenue base, but renal indications are needed to support sales above $3 billion.
  • The product competes against infused C5 inhibitors, pegcetacoplan and emerging oral complement inhibitors.
  • Fabhalta faces generic, not biosimilar, risk.
  • As of June 2024, no major public Paragraph IV challenge had created a defined near-term launch threat.
  • Regulatory exclusivity extends into the late 2020s, while orphan exclusivity for PNH would ordinarily run into December 2030.
  • The ultimate generic-entry date depends on the issued patent estate, Orange Book listings, patent-term adjustments and litigation settlements.
  • The base-case commercial outlook is approximately $2 billion-$3.5 billion in peak annual sales, with upside above $4 billion if C3G and IgAN adoption is strong.

FAQs about LNP023 and Fabhalta

What is the generic name of LNP023?

The generic name is iptacopan. Novartis markets it in the United States as Fabhalta.

Is iptacopan a biologic or a small molecule?

Iptacopan is an orally administered small-molecule factor B inhibitor. It is not a monoclonal antibody and will not face biosimilar competition.

What diseases is iptacopan being developed to treat?

The lead indications are PNH, C3G and IgAN. PNH is approved in the United States, while C3G and IgAN were under phase 3 development as of June 2024.

What is the main advantage of Fabhalta over ravulizumab?

Fabhalta is administered orally and inhibits the alternative pathway upstream at factor B. Ravulizumab is an intravenous C5 inhibitor with less frequent dosing but continued infusion administration.

Could Fabhalta replace C5 inhibitors in PNH?

It could replace C5 inhibitors for some patients, particularly those with residual anemia or a preference for oral treatment. Switching will depend on clinical response, safety, physician practice and payer policy.

Sources

  1. European Commission. (2024). Fabhalta: European public assessment and authorization information. European Medicines Agency.

  2. Novartis. (2023). Novartis Fabhalta approved by FDA to treat adults with paroxysmal nocturnal hemoglobinuria. Novartis.

  3. Novartis. (2024). Annual report 2023. Novartis AG.

  4. U.S. Food and Drug Administration. (2023). Fabhalta prescribing information. U.S. Department of Health and Human Services.

  5. U.S. Food and Drug Administration. (2023). FDA approves first factor B inhibitor for adults with paroxysmal nocturnal hemoglobinuria. U.S. Department of Health and Human Services.

  6. ClinicalTrials.gov. (2024). APPEAR-C3G, APPLAUSE-IgAN, APPLY-PNH and APPOINT-PNH clinical trial records. U.S. National Library of Medicine.

  7. U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information. U.S. Department of Commerce.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.